ID: ALA5208483

Max Phase: Preclinical

Molecular Formula: C20H17ClFN3OS

Molecular Weight: 401.89

Representations

Canonical SMILES:  O=C(Nc1cccc(Cl)c1)N1CCC[C@H]1c1nc(-c2ccc(F)cc2)cs1

Standard InChI:  InChI=1S/C20H17ClFN3OS/c21-14-3-1-4-16(11-14)23-20(26)25-10-2-5-18(25)19-24-17(12-27-19)13-6-8-15(22)9-7-13/h1,3-4,6-9,11-12,18H,2,5,10H2,(H,23,26)/t18-/m0/s1

Standard InChI Key:  FFSXDIJYAHMWKK-SFHVURJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 401.89

Molecular Weight (Monoisotopic): 401.0765

AlogP: 5.97

#Rotatable Bonds: 3

Polar Surface Area: 45.23

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.03

CX Basic pKa: 1.07

CX LogP: 5.18

CX LogD: 5.18

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.59

Np Likeness Score: -1.92

References

1. Qiao Y, Zhang Y, Qiao Z, He W, Chen Y, Song D, Wang G, Guo N, Shao L, Tian Z, Wang Q, Yan L, Qian H..  (2022)  Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist.,  233  [PMID:35263708] [10.1016/j.ejmech.2022.114191]

Source

Source(1):

• Scientific Literature